Group One Trading
BCTX

Group One Trading’s Briacell Therapeutics BCTX Stock Holding History

Group One Trading’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-141
Closed -$24.2K – 6647
2024
Q2 		$24.2K Sell
141
-7
-5% -$1.98K ﹤0.01% 5085
2024
Q1 		$63.5K Buy
148
+104
+236% +$57.3K ﹤0.01% 4514
2023
Q4 		$38.6K Sell
44
-1
-2% -$718 ﹤0.01% 5261
2023
Q3 		$42.5K Buy
+45
New +$44K ﹤0.01% 5258

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Group One Trading's BCTX Position: Q1 2026 in Review

Group One Trading reduced its Briacell Therapeutics (BCTX) stake by 77% in Q1 2026, selling an estimated $251 and leaving 16 shares worth $67. The position accounts for ﹤0.01% of the portfolio, ranked #7438.

Group One Trading first reported a position in BCTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $47K in Q3 2024. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • Group One Trading held 16 shares of Briacell Therapeutics worth $67 as of Q1 2026.
  • Group One Trading sold 54 Briacell Therapeutics shares in Q1 2026, an estimated $251.
  • Briacell Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #7438 holding.
  • Group One Trading first reported a position in Briacell Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Group One Trading's Briacell Therapeutics position peaked at $47K in Q3 2024.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.